The placenta is critical for all aspects of fetal development. Bisphenol A (BPA) and phthalates are endocrine disruptors with ubiquitous exposure in pregnant women-their effects on the placenta is an area of growing research interest. Therefore, our objectives were to (1) summarize research related to the effects BPA or phthalates on placental outcomes in animal and cell models, and (2) evaluate the challenges for using such models to study the impacts of these chemicals on placental endpoints. Overall, studies in cells and animal models suggest that BPA and phthalates impact placental hormones, some epigenetic endpoints, increase inflammation and oxidative stress, and decrease cell viability and nutrient transfer. However, few animal or cell studies have assessed these outcomes at concentrations relevant to humans. Furthermore, it is unclear whether effects of BPA/phthalates on the placenta in animal models mediate fetal outcomes, as most studies have dosed after the earliest stages of placental and fetal development. It is also unclear whether effects of these chemicals are sex-specific, as few studies have considered placental sex. Finally, while there is substantial evidence for effects of mono-(2-ethylhexyl) phthalate (the major metabolite of di-(2-ethylhexyl) phthalate), on placental endpoints in cells, little is currently known about effects of other phthalates to which pregnant women are exposed. Moving forward, these limitations will need to be addressed to help us understand the precise mechanisms of action of these chemicals within the placenta, and how these reported perturbations impact fetal health.
Bisphenol A (BPA) and phthalates are endocrine disrupting chemicals found in food packaging and personal care/household products (Mervish et al., 2014; Schettler, 2006) . Although life-course exposures to these chemicals can adversely impact health, pregnancy is an especially sensitive window, and epidemiological studies demonstrate that pregnant women have widespread exposure to these chemicals Yan et al., 2009) . In placental mammals, the establishment and maintenance of a successful pregnancy, and the offspring's lifelong health, rely on finely tuned developmental trajectories of placental and fetal tissues (reviewed in Godfrey, 2002 and Powell, 2007) . As we have reviewed elsewhere (Strakovsky and Schantz, 2018) , recent human studies suggest associations between BPA or phthalate exposures and numerous placental molecular endpoints. These include hormone-related mRNA expression (Adibi et al., 2010 (Adibi et al., , 2017 , micro-RNA expression (LaRocca et al., 2016; Zhong et al., 2018) , long noncoding RNA expression , and DNA methylation (Grindler et al., 2018; LaRocca et al., 2014; Nahar et al., 2015; Zhao et al., 2015 Zhao et al., , 2016 . Furthermore, there is evidence that phthalate exposure in humans is also associated with changes to placental anthropometry (length, breadth, surface area, and thickness) . However, the current literature in humans is still limited in its ability to pinpoint specific mechanisms by which these chemicals target the human placenta to cause these effects and to ultimately impact placental function.
These knowledge gaps are due, in part, to the challenges in assessing phenotypic and molecular endpoints within the large and heterogeneous human placenta, with studies showing that even the most careful sampling schemes to assess gene expression can result in great within-placental variability (Adibi et al., 2009) . Other challenges for making mechanistic evaluations within the human placenta thus far have included the following: (1) the fact that chemical exposures have been assessed at various points in pregnancy, whereas placental tissues are typically only available at birth, and (2) lack of reliable information about the role of fetal sex in modifying associations of exposures with placental molecular endpoints. As will be discussed throughout this review, there are undoubtedly challenges for modeling placental outcomes in experimental animal and cell models. Nevertheless, given the difficulties that exist in human placental sampling, such models are invaluable for unraveling the mechanisms of action of environmental chemicals within the placenta. The primary goal of this review is to address these challenges and opportunities for modeling placental structural, functional, and molecular outcomes in response to BPA and phthalates.
ANIMAL MODELS
Given the challenges in both human exposure assessment and placental sampling, animal models are important for assessing the underlying mechanisms behind the associations observed in humans. First, unlike in humans, the small size of the rodent placenta allows for histological evaluation of whole placentas as well as for site-and structure-specific molecular analysis in response to chemical exposures. Second, rodent models provide excellent opportunities for sex-specific evaluations of the placental-fetal unit, given that each rodent pup develops with its own placenta. As will be described below, important factors to consider when designing such models include the structural, functional, and epigenetic differences between species, exposure window, chemical dose, and placental sex, among others (Tables 1 and 2 ).
Animal Model Selection
Although the rodent is the most-widely utilized animal model in studies assessing the effects of BPA and phthalates on the placenta, there are important developmental and structural differences between human and rodent placentas (reviewed in Carter, 2007 ) (cited and reviewed in Figure 1 ). These differences include placental hormone synthesis and function ( Figure 1A ), trophoblast invasion, remodeling of spiral arteries that carry blood and nutrients to the fetus, the timing and process of decidualization and placental development, the formation and branching of villi ( Figure 1B) , and the fetal: placental weight ratio, which is driven by fundamental species differences in maternal-fetal blood flow ( Figure 1C) . Despite these differences, there are numerous reasons for using rodent models to study the effects of environmental chemicals on the placenta. First, like humans, rodents develop a single discoid placenta. Humans and rodents also both have a hemochorial placenta, in which fetal chorionic villi are directly bathed by maternal blood ( Figure 1D ). In regard to epigenetic regulation, aspects of placental imprinting differ between rodents and humans (Monk et al., 2006) . However, given that genomic imprinting is important for both human and rodent placental development (Frost and Moore, 2010) , rodent studies have been useful for assessing the capacity of environmental chemicals to disrupt placental imprinting. Other useful models of human placental development also exist, and include nonhuman primates and sheep. However, few studies using these models have assessed the effects of endocrine disruptors on placental endpoints (except 1 study in sheep discussed later), therefore here, we have focused primarily on currently available studies in rodents.
Exposure Timing
Developmental toxicity studies targeting specific windows of fetal organ development are valuable for gaining insight into fetal organogenesis. However, the role of the placenta in mediating these outcomes is difficult to assess if dosing begins after the earliest stages of implantation and placental development/trophoblast invasion (as early as gestational day [GD] 3.5 in mice) (Yamanaka et al., 2006) . Furthermore, these studies do not accurately model exposures in humans, as women are exposed to BPA and phthalates on a daily basis, prior to and throughout pregnancy.
Of the studies described here, only one began dosing prior to mating, whereas others started on GD 0 or 1, or much later (Tables 1 and 2 ). However, there is evidence for windowspecific effects of phthalates on placental pathology. A recent study in ICR mice dosed with high-dose (500 mg/kg) di-(2-ethylhexyl) phthalate (DEHP) found decreased placental weight and diameter (males only) and decreased blood sinusoid area and cell proliferation (males and females analyzed together) only in dams dosed at GD7-12, but not GD0-6 or GD13-17 . Timing of exposure is especially significant when assessing placental epigenetic endpoints, as the earliest rapid stages of placental cell differentiation occur under strict epigenetic control (Maltepe et al., 2010) . In JF1 mice, neither BPA (0.2 mg/ kg/day) nor DEHP (750 mg/kg/day) gavaged from GD8.5 to GD12.5 had major effects on loss-of-imprinting or the expression of imprinted genes (Kang et al., 2011) . BPA also had no effect on either placental or embryonic loss-of-imprinting in pregnant C57BL/6 dosed from GD5.5 to GD12.5 (Susiarjo et al., 2013) . However, when the C57BL/6 mice were dosed with BPA beginning two weeks prior to mating until GD9.5 or GD12.5, BPA disturbed loss-of-imprinting, altered the mRNA expression of several imprinted genes, reduced placental CpG and average global DNA methylation, and decreased DNA methylation of 1 imprinted gene (Susiarjo et al., 2013) . Although germline imprints (those passed to future generations) resist the first wave of active demethylation immediately following fertilization (Sanz et al., 2010) , the earliest regulation of placental imprinting occurs, in part, independently of DNA methyltransferase 1 (DNMT1) mechanisms that regulate extra-placental imprinting (Court et al., 2014) . These early dynamic processes may be especially sensitive to disruption by environmental chemicals. Therefore, given the role of epigenetics in regulating transcription, downstream translation, and ultimately placental development, it is critical that studies assessing the effects of chemicals on the placenta begin dosing prior to mating or immediately following fertilization.
Bisphenol dose and compound selection. Animal studies assessing nonplacental endpoints suggest a nonmonotonic doseresponse for BPA, likely reflecting effects on both endocrine and 
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non-endocrine pathways. Placental studies, however, have thus far utilized relatively high doses and limited dose-response curves. Despite this, several studies do suggest a dose-response relationship for BPA. For example, in ICR mice, most effects on placental mRNA and protein expression were observed only at the higher BPA doses (200 and 20 mg/kg vs 2 mg/kg) (Tan et al., 2013) . In a study using CD-1 mice, 0.5 versus 50 mg/kg/day BPA also had dose-dependent effects on placental size, size of the spongiotrophoblast layer, total areas of maternal blood spaces, and embryonic labyrinthine capillaries. In this study, of all genes affected by 0.5 or 50 mg/kg BPA (compared with control), only 77 were shared between the 2 treatment groups, with 0.5 mg/kg BPA generally having a larger effect than 50 mg/kg. The 2 BPA doses also led to different significantly enriched KEGG pathways and different affected protein hubs (Tait et al., 2015) . BPA has also been shown to dose-dependently affect epigenetic endpoints in other tissues (Ho et al., 2015) , and while the Susiarjo et al. study demonstrated dose-dependent effects on placental imprinting and DNA methylation, and included a lower dose of BPA (estimated 10 mg/kg bw/day), additional studies are warranted using wider ranges of doses, including those more in line with human exposures (estimated to be well <1-2 mg/kg bw/day in the general population; Teeguarden and Hanson-Drury, 2013).
Only one animal study has assessed the effects of bisphenols other than BPA. Interestingly, a study in sheep found that bisphenol S (BPS), which is currently being used as a replacement for BPA in many products, altered the expression of syncytialization-related proteins/mRNA and decreased the number of trophoblast-derived binucleate cells, whereas the same dose of BPA had no effect on these outcomes (Gingrich et al., 2018) . Pregnant women are exposed to various bisphenols (Kolatorova et al., 2018; Wan et al., 2018) , so additional studies in animals may be warranted to investigate the effects of these compounds on the placenta.
Phthalate dose and compound selection. Animal studies assessing effects of phthalates on placental endpoints are also limited, have utilized relatively high doses, and have primarily focused on 1 phthalate, DEHP. In pregnant CD-1 mice, DEHP (125, 250, or 500 mg/kg/day) had dose-dependent effects on total placental and labyrinthine area, whereas all DEHP doses altered placental weight, spongiotrophoblast area, small-branched fetal vessels, proliferation in several placental zones, and the mRNA expression of numerous genes (Zong et al., 2015) . In Sprague Dawley rats, DEHP (750 or 1500 mg/kg/day) dose-and zone-specifically induced placental mRNA and protein expression of Ppara and Pparg, the expression of several fatty acid transport-related HUMANS: placenta expresses steroidogenic genes throughout pregnancy (Ben-Zimra et al. 2002) and expresses βCG (Maston and Ruvolo 2002) .
MICE: placenta does not appear to express steroidogenic genes in the second half of gestaƟon (Ben-Zimra et al. 2002) . RODENTS: placenta releases lactogens (Freemark et al. 1993 ), but does not appear to express βCG (Maston and Ruvolo 2002) .
Trophoblast invasion:
HUMANS: deep (Adamson et al. 2002) . MICE: shallow. RAT: myometrial invasion and arterial remodeling much more similar to humans than to mice. (Vercruysse et al. 2006) .
HUMANS: approximately 6:1; RATS -10:1 (Leiser and Kaufmann 1994) . MICE: reported as 11:1 to 14.5:1 (Coan et al. 2008 ).
HUMANS and RODENTS: discoid.
• Other species have alternate structures (zonary in cats and dogs, cotyledonary in cow and sheep, diffuse in pigs and horses).
A. Placental Hormones B. Trophoblast Invasion and DecidualizaƟon

C. Fetal:Placental Weight RaƟo D. Structure and ClassificaƟon
Placental growth hormone: regulates maternal IGF-1 release -controls maternal metabolic adaptaƟon to pregnancy together with placental lactogen (Lacroix et al. 2002; Newbern and Freemark 2011) .
Estrogen: supports fetal growth -increases placental angiogenesis & fetal nutrient transfer (Albrecht and Pepe 2010) ; involved in implantaƟon & parturiƟon (Padmanabhan and Laloraya 2016; Vannuccini et al. 2016) .
hCG: numerous roles in placental development, including promoƟng progesterone producƟon (Cole 2010) . Progesterone:
• Increases maternal food intake (Douglas et al. 2007 ).
• Suppresses maternal immune response to fetus by supporƟng the shiŌ from TH1 (cell-mediated) immune acƟvity to TH2 (humoral) acƟvity (Challis et al. 2009 ). HUMANS: produced by the placenta; concentraƟons much higher than in mice. MICE: produced by the corpus luteum throughout gestaƟon. (Malassine et al. 2003) .
DecidualizaƟon:
HUMANS: during the late secretory phase of the menstrual cycle in preparaƟon for pregnancy. RODENTS: in response to implantaƟon at 4-5 days of pregnancy. (Fonseca et al. 2012 ).
Villi formaƟon and branching:
HUMANS -as early as 13 days post-coitum (Benirschke and Kaufmann 1995) . MICE -not unƟl embryonic day 8.5 (Murray et al. 2010) when the embryo fuses with the chorion (Rossant and Cross 2001) .
Ability to produce more fetus per gram of placenta likely due to:
• Rodents' placental countercurrent blood exchange (Kaufmann and Davidoff 1977) .
• Differences in placental passive solute permeability between humans and rodents (Sibley 2009 ).
• Differences in the number of trophoblast layers between fetal and maternal blood (3 in the mouse and rat, and 1 in humans) (Leiser and Kaufmann 1994) . • In other species, fetal Ɵssues of the placenta are not directly exposed to maternal blood (epitheliochorial in horses and ruminants or endotheliochorial in dogs and cats (Leiser and Kaufmann 1994) .
HUMAN and RODENTS: hemochorial (Grosser
Figure 1. Species differences (specifically focusing on humans and rodents) in A, placental hormones, B, trophoblast invasion and decidualization, C, the fetal: placental weight ratio, and D, placental structure and classification (Adamson et al., 2002; Albrecht and Pepe, 2010; Benirschke and Kaufmann, 1995; Ben-Zimra et al., 2002; Challis et al., 2009; Coan et al., 2008; Cole, 2010; Douglas et al., 2007; Fonseca et al., 2012; Freemark et al., 1993; Kaufmann and Davidoff, 1977; Lacroix et al., 2002; Leiser and Kaufmann, 1994; Malassine et al., 2003; Maston and Ruvolo, 2002; Murray et al., 2010; Newbern and Freemark, 2011; Padmanabhan and Laloraya, 2016; PrabhuDas et al., 2015; Rossant and Cross, 2001; Sibley, 2009; Vannuccini et al., 2016; Vercruysse et al., 2006) .
genes/proteins, and placental content of several long-chain polyunsaturated fatty acids. However, both doses induced cytochrome p4504A1 (CYP4A1) mRNA and protein, and reduced labyrinthine cyclooxygenase (COX)-2 protein and prostaglandin formation from placental homogenates (Xu et al., 2008) . It is likely that the lack of a dose-response in these studies was due to the high phthalate doses used in these experiments, which were chosen because previous studies had used similar doses, and not because they were relevant to human exposures. Authors discussed that approximate plasma concentrations of mono-(2-ethylhexyl) phthalate (MEHP) (the major metabolite of DEHP) in healthy women at term are 2.05 6 1.47 lg/ml (referenced from Latini et al., 2003) . However, authors of this animal study discussed unpublished results showing that 750 and 1500 mg/kg DEHP treatment led to maternal MEHP plasma concentrations of 65 or 136 lg/ml (respectively). Given that these internal doses are greatly out of the range of human exposures, additional studies using lower concentrations of DEHP are needed to corroborate these findings. Two more-recent studies reported placental outcomes in response to phthalates other than DEHP, but also at relatively high doses. In Wistar rats, 500 mg/kg DBP dosed to the F0 generation decreased placental weight in F1, F2, and F3 generations, accompanied by numerous reproductive and developmental disturbances in offspring (Mahaboob Basha and Radha, 2017) . Another study in Wistar rats found that all doses (20, 100, 500 mg/kg) of di-n-hexyl phthalate (DHP) or dicyclohexyl phthalate (DCHP) decreased placental protein expression of PCNA, PPARc, ERa, ERb, and AR. However, effects on placental weight, diameter, and length differed by chemical and dose, as did most pathological findings within the trophoblasts, spongiotrophoblast, and basal zone (Ahbab et al., 2017) . Although this study included a dose-response curve, even the lowest concentration (20 mg/kg) may not be relevant to human exposures, as urinary MCHP (the major metabolite of DCHP) was below the level of detection for most people in the recent NHANES (CDC, 2017), and little is known about human DHP exposure.
Based on these findings, studies with more extensive doseresponse curves that are more in line with human exposures will be essential to begin unraveling the mechanisms responsible for associations of phthalates and BPA exposures with placental outcomes in humans. This task is complicated by species differences in toxicokinetics, exposure, metabolism, and elimination rates of both BPA and phthalates (Doerge et al., 2011; Rusyn et al., 2006; Silva et al., 2007; Thayer et al., 2015) . In humans, exposure is estimated based on internal doses of parent compounds or excretion of their metabolites. In animals, however, doses of parent compounds are known, but not the circulating or excreted concentrations of chemicals and their metabolites. Establishing exposure "dose" in humans is difficult given the multiple exposure pathways for BPA and phthalates and the paucity of data on human pharmacokinetics of these compounds. Therefore, in future animal studies, assessment of circulating and excreted concentrations of chemicals and their metabolites will be critical to allow exposure/dose comparisons between humans and model animals.
Sex-specific placental outcomes. The placenta develops from both maternal and fetal tissues, and consequently has sexually dimorphic responses to environmental and dietary cues (Rosenfeld, 2015) . Studies in humans do suggest sex-specific associations between exposure to BPA or phthalates and placental outcomes (Adibi et al., 2017; LaRocca et al., 2014) . However, of the animal studies described here, only 2 specifically discussed "placental sex." In ICR mice, 200 mg/kg DEHP decreased placental weight and diameter in male but not female placentas , whereas 2.5 lg/kg/day BPA differentially affected placental mRNA expression depending on placental sex, either in magnitude or direction (Imanishi et al., 2003) . As previously discussed, rodent models are especially useful for assessing sex-specific associations between placental and fetal outcomes, as each pup develops with its own placenta. Given the reported sexually dimorphic associations of BPA/phthalates with placental outcomes in humans and some previous animal studies, future animal models should leverage the rodent fetal-placental unit to assess sex-specific placental effects of BPA and phthalates.
IN VITRO SYSTEMS
Cell culture experiments are indispensable for establishing mechanisms of action of BPA and phthalates on placental function. In placental in vitro models, these functional/phenotypic endpoints include standard measures of cell health (viability, proliferation, necrosis), and placenta-specific measures of function and development (apoptosis, migration, invasion, and differentiation). Similar to cancer, appropriate placental development is characterized by increased migration, invasion, differentiation (Knofler and Pollheimer, 2013) , and apoptosis (which is exaggerated in instances of placental disease; Sharp et al., 2010) , thereby providing phenotypic readouts for the effects of BPA and phthalates. As will be discussed in following sections, similar to animal models, chemical concentration and length of exposure are critical for assessing effects of these chemicals, as is model selection. Models utilized in currently available studies include classic immortalized cell lines, as well as more physiologically relevant placental primary cultures to more-accurately model placental exposures (Tables 3 and 4) .
Cell Models
Models assessing the impacts of environmental chemicals on placental molecular signaling have included immortalized cell lines, primary trophoblasts, cytotrophoblasts, microsomes, chorionic villi explants, and placental macrophages. For both immortalized and primary cells, the differences between their signaling and physiological responses to treatments represent fundamental differences in physiological functions of cells from which they are derived (Bilban et al., 2010) . For example, in human HTR-8/SVneo placental cells, BPA had no effect on cell viability or proliferation, whereas a range of BPA concentrations decreased cell migration and invasion, reflecting the invasive nature of these first-trimester-derived trophoblasts (Spagnoletti et al., 2015) . The invasive nature of HTR-8/SVneo cells was confirmed in another study, showing that BPA increased MMP-9 (but not MMP-2) protein, involved in cell invasion and migration (Lan et al., 2017) , and both proteins were increased by BPA in BeWo cells, a first-trimester-derived trophoblast choriocarcinoma cell line (Wang et al., 2015) .
Differences in gene transcription underlie the functional differences between placental cell lines and cell types, and may likely regulate their response to environmental chemicals. For example, in both JEG-3 choriocarcinoma immortalized cells and PL30 cells derived from third-trimester placentas, BPA concentration-dependently inhibited CYP19 gene expression, but the baseline expression of CYP19 appeared to be much greater in JEG-3 than in PL30 cells, reflecting the innate differences of an important hormonal regulator between these cells (Huang and Leung, 2009) . A microarray study in several Authors suggested that these contrasting responses to BPA are likely due to stage-specific differences between cell lines, as HTR-8 cells are derived from first trimester extravillous cells from the termination of a normal pregnancy and 3 A cells from first trimester villous cells, whereas TCL-1 cells come from third trimester villous cells. Although this is a possible explanation, the maintenance and growth of these cells often varies depending on the supplier and even from lab-to-lab, so additional systematic studies may be needed to confirm these findings in primary cell lines. The mechanisms by which BPA targets the placenta are still largely unknown, but there is some evidence that different cells may uniquely interact with specific toxicants. The estrogenrelated receptor gamma (ERRc1), a receptor that binds BPA with high affinity, has been suggested to drive the preferential accumulation of BPA within the placenta (Takeda et al., 2009) . In one study, the baseline mRNA expression of ERRc1 was higher in JEG-3 and human isolated extravillous cytotrophoblasts than in BeWo cells. Importantly, the expression of ERRc1 was 20-25 and 50-fold higher in first and third trimester placentas, respectively, when compared with JEG-3 cells. Other ERRc subtypes (ERRc2 and ERRc3) were not expressed at all in JEG-3 or BeWo cells, but were expressed in first-trimester placentas. Furthermore, in JEG-3, but not BeWo cells, BPA concentrationdependently decreased a marker of DNA synthesis rate partly through ERRc (Morice et al., 2011) . These studies in a variety of cell models suggest that, as with well-known cell models of cancer initiation, progression, and metastasis, future placental studies must select cell models based on their genetic and developmental characteristics. For example, immortalized cells from first trimester placentas (eg, HTR-8, BeWo, JEG-3) may be better suited for studies related to invasion and vascularization, whereas third trimester immortalized cells (eg, TCL-1) or primary cells from term placentas may be best when assessing effects on placental nutrient transfer or hormonal signaling.
BPA Concentration and Treatment Length
BPA's nonmonotonicity and mechanism-of-action require careful selection of both treatment concentrations and timing. For example, in human placental chorionic villi explants, BPA increased a proinflammatory cytokine associated with immune adaptations in pregnancy after 24 h of treatment, but the effect was absent at 48 h (Mannelli et al., 2014) . In primary cytotrophoblasts from term placentas of uncomplicated pregnancies treated with 0.0002 to 0.2 lg/ml BPA, apoptosis was induced by 0.02-200 lg/ml BPA, but not by the 2 lower concentrations, whereas necrosis and tumor necrosis factor a (TNF-a) mRNA and protein were induced by the lower BPA concentrations. Conversely, several higher concentrations of BPA had no effect on TNF-a mRNA, decreased TNF-a protein, and decreased necrosis (Benachour and Aris, 2009) . In primary cultures of human placental trophoblasts, 11-b-dehydrogenase isozyme 2 (11b-HSD2) activity, protein content, and gene expression were also concentration-dependently increased by BPA (increased by 0.25-2.0 lg/ml but not 0.1 lg/ml BPA) (Rajakumar et al., 2015) . Another study in placental explants showed that in term but not first trimester placental villus cultures, 48-h treatment with 1 nM but not 100 nM BPA decreased the ABCG2 protein, which transports a variety of compounds in human placental syncytiotrophoblasts (Sieppi et al., 2016) , highlighting the importance of both chemical concentration and developmental timing.
Similarly, in immortalized cells, the mRNA and protein expression of CRH in JEG-3 cells was increased by 25 and 50 lM BPA, but not by 1 or 5 lM BPA (Huang et al., 2012) . In addition, in JEG-3 cells, BPA had both time-and concentration-dependent effects on aromatase activity, increasing activity at some concentrations and treatment windows and decreasing activity at others (Nativelle-Serpentini et al., 2003) . In BeWo cells, BPA increased cell proliferation at 1 and 10 lM, whereas other concentrations (0.01, 0.1, and 100 lM) had no impact on proliferation, and the highest concentration (1000 lM) decreased proliferation. These outcomes were accompanied by dose-specific effects on E-cadherin mRNA and protein, but relatively consistent effects across doses on invasion and markers of invasion (MMP-9, MMP-2, TIMP-1, and TIMP-2 protein) (Wang et al., 2015) . Similarly, in HTR-8/SVneo cells, BPA had both concentrationand time-specific effects on cell migration and concentrationspecific effects on markers of invasion (MMP-9 and TIMP-3 protein) (Lan et al., 2017) . Taken together, these studies confirm the concentration-and time-dependent nature of BPA's effects on downstream targets and highlight the importance of selecting physiologically relevant concentrations and treatment lengths for investigating potential mechanisms of action of BPA using in vitro models. Specifically, many of these studies support the nonmonotonicity of BPA-where effects on some pathways were only observed at lower or higher concentrations, whereas other pathways were targeted by the lowest and highest, but not middle BPA concentrations. This suggests that while both low and high concentrations of BPA impact placental pathways, BPA's mechanisms of action may differ at the 2 ends of the dose-response curve. These data also reinforce the need for extensive dose-response curves that first: include the expected range of exposure in humans and second: allow for the interpretation of BPA concentration-specific mechanisms-of-action within the placenta.
Phthalate Concentration and Treatment Length
Numerous in vitro studies have assessed the effects of MEHP, the major DEHP metabolite, on placental cellular endpoints. For example, CRH and COX-2 regulate parturition in humans and have been linked with preterm birth, and in human placental cytotrophoblasts, only higher concentrations of MEHP (100 lM and 150 lM) increased the expression of these proteins . In HTR-8/SVneo cells treated with a range of MEHP concentrations, only the highest concentration (180 lM) increased ROS production, oxidative DNA damage, and apoptosis, whereas both 90 and 180 lM concentrations induced the mRNA expression of prostaglandin-endoperoxide synthase 2 (PTGS2/ COX-2) (Tetz et al., 2013) . In THP-1 cells (human monocyte cells derived from an infant with acute monocytic leukemia), this group later showed that only the highest concentration (180 lM, after 24 h of treatment, not 2-8 h) induced prostaglandin E2 release (Tetz et al., 2015) . A more recent study in HTR-8/SVneo cells showed that invasion was decreased and TIMP-1 protein increased by 10, 100, and 200 lM MEHP, but not by the lowest concentration (1 lM), whereas MMP-9 activity was only decreased at 100 and 200 lM MEHP (Gao et al., 2017) . In addition, in HTR-8/SVneo cells, 50, 100, or 180 lM MEHP induced ROS production, but the most pronounced effects were at the highest concentration and primarily after 72 h. In another study, 50 lM MEHP had no effect on miR-16 (which authors discussed is altered in pregnancy pathologies), whereas 100 lM MEHP increased miR-16 at 4 and 48 h, and 180 lM increased miR-16 at all timepoints (4, 8, 24 , 48 h) (Meruvu et al., 2015) . The same group later showed that intracellular ROS production in HTR-8/SVneo cells was increased by a range of MEHP concentrations, but the expression of several miRs was only increased at higher concentrations (100 or 180 lM), with the exception of miR-17-5p (Meruvu et al., 2016) . These concentrations correspond to 30 and 54 lg/ml MEHP (respectively), whereas pregnant women have been shown to have much lower median plasma concentrations of 0.68 6 0.85 lg/ml (Latini et al., 2003) , and ranging from 0.17 to 6.74 lg/ml (Li et al., 2013) . These studies suggest that most MEHP concentrations affect transcription and translation, but that cellular phenotypic changes are typically only observed at higher MEHP concentrations. It is possible that the expected chronic low-dose MEHP exposure in humans can be modeled in cells with short-term treatment at higher concentrations. However, it is more likely that as with BPA, MEHP's mechanisms-ofaction differ at the extremes of the concentration curve. Therefore, in order to understand the mechanisms by which MEHP affects the placenta, more studies are warranted assessing a variety of endpoints using broader and more humanrelevant concentration curves.
As previously described, pregnant women are exposed daily to an array of phthalates. However, few cell studies have assessed outcomes in response to DEHP metabolites other than MEHP. However, 2 in vitro studies treated rat HRP-1 placental cells with DEHP or 2 of its metabolites, MEHP and 2-ethylhexanoic acid (EHA). DEHP and both metabolites had concentrationand time-specific effects on the expression of placental fatty acid uptake and metabolism-related genes. All 3 also increased the uptake rates of several essential fatty acids, whereas only MEHP and EHA increased arachidonic acid transport, and only DEHP increased DHA transport (Xu et al., 2005) . In a follow-up study in HRP-1 cells, DEHP, MEHP, and EHA also had unique effects on the overall contents of several lipid classes (Xu et al., 2006) .
Another current limitation in the field is that only 2 in vitro studies thus far have investigated phthalates other than DEHP and its metabolites. One assessed the structure-activity relationship of 100 lM of 11 diphthalates and 3 monophthalates on progesterone and estradiol production in JEG-3 cells. Estradiol production was only decreased by DCHP and BBOP, whereas 5 diphthalates decreased progesterone production, with no effects of monophthalates on either hormone (Table 4) , suggesting that the ability of phthalates to inhibit aromatase and 3b-hydroxysteroid dehydrogenase 1 (3b-HSD1), and to decrease estradiol and progesterone production is highly dependent on their chemical structure. Another study treated JEG-3 cells with 0.01-500 lM DMP, DBP, BBP, and DEHP. None of the phthalates affected ROS production, but DMP increased aromatase activity at concentrations >50 lM, DBP and BBP decreased aromatase activity at IC50 ¼ 104 and 167 lM (respectively), whereas DEHP had no effect on aromatase activity (PerezAlbaladejo et al., 2017) . Phthalate mixtures used in other experimental models have shown their distinct phenotypic effects compared with DEHP alone (Zhou et al., 2017a,b) . Such approaches in placental studies will be valuable for establishing these chemicals' mechanisms of action when present as complex mixtures, as they are in humans.
CONCLUSIONS AND FUTURE DIRECTIONS
Placental Actions of BPA and Phthalates As summarized in Tables 1-4 , studies assessing effects of BPA or phthalates on placental outcomes in experimental animal and cell models have focused on hormones, epigenetics, inflammation/oxidative stress, cellular damage, and nutrient transfer.
BPA and phthalates are known endocrine disruptors, and there is substantial evidence that BPA can disrupt placental hormones, their receptors, or regulatory enzymes, whereas studies related to the effects of phthalates on placental hormones are more limited. In addition to hormones, placental nutrient transfer capacity is the best-characterized measure of placental efficiency (Burton and Fowden, 2012) . Therefore, more studies are warranted in all models to investigate the effects of BPA and phthalates on placental energy metabolism, and fetal nutrient supply.
Although there is great interest in the role of epigenetics in placental development, additional data are needed related to the ability of BPA and phthalates to disrupt placental epigenetic signaling in experimental models. Currently, evidence for the ability of BPA or phthalates to induce placental inflammation or oxidative stress comes primarily from cell models; given that oxidative stress and inflammation are proposed to mediate associations of BPA or phthalate exposure with pregnancy outcomes (Ferguson et al., 2017; Veiga-Lopez et al., 2015; Watkins et al., 2015) , more studies in animal and cell models are warranted to investigate these mechanisms. Finally, there is substantial evidence from experimental models that BPA and phthalates cause frank damage to placental vasculature, structure, and function. However, these findings should be substantiated in animal models using concentrations of both chemicals that are in line with human exposures.
Summary of Animal and Cell Models
Given the challenges in human placental sampling (Figure 2) , various experimental models have been employed to address mechanisms of placental disruption by BPA and phthalates. However, these studies vary in their design and measured outcomes, and few accurately reflect human exposures to these chemical. Therefore, both animal and cell models would benefit from use of more extensive BPA/phthalate doses and concentrations (Figure 2) . Furthermore, exposures in animal models should ideally begin prior to decidualization, and treatment in cell models should be timed appropriately, with more extensive time ranges. Assessing sex-specific outcomes in animal models is also critical, as is the selection of precisely applicable cell models. In the case of phthalates, future animal and cell studies should assess exposure to a wider variety of phthalates (beyond DEHP and its metabolites), and at more relevant doses, with the ultimate goal of modeling more complex exposures to the mixtures of phthalates that occur in humans. Finally, given broad outcome selection in animal and cell models, a useful approach moving forward would be to design mechanistic animal and cell studies that parallel placental endpoints altered in humans in response to BPA and phthalates. Such approaches will be indispensable in helping to unravel the mechanisms involved in placental toxicity and the placenta-mediated effects of EDCs on fetal development.
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To accomplish this, as illustrated in the figure, numerous factors should be carefully considered when establishing animal and in vitro models, and using findings from animal or in vitro studies to inform questions in humans. Furthermore, these factors should be taken into account when drawing conclusions regarding mechanisms of action of BPA and phthalates from the currently available literature.
